Cancer Cell Biology

You have full text access to this OnlineOpen article

Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases

  1. Guojun Bu1,
  2. Wenyan Lu2,
  3. Chia-Chen Liu1,
  4. Katri Selander3,
  5. Toshiyuki Yoneda4,
  6. Christopher Hall5,
  7. Evan T. Keller5,
  8. Yonghe Li2,*

Article first published online: 10 JUN 2008

DOI: 10.1002/ijc.23625

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1034–1042, 1 September 2008

Additional Information

How to Cite

Bu, G., Lu, W., Liu, C.-C., Selander, K., Yoneda, T., Hall, C., Keller, E. T. and Li, Y. (2008), Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. Int. J. Cancer, 123: 1034–1042. doi: 10.1002/ijc.23625

Author Information

  1. 1

    Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

  2. 2

    Departments of Biochemistry and Molecular Biology, Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL

  3. 3

    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

  4. 4

    Endocrine Research, Department of Medicine, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX

  5. 5

    Department of Urology, University of Michigan, Ann Arbor, MI

*Department of Biochemistry and Molecular Biology, Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35255-5305

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 10 JUN 2008
  3. Manuscript Accepted: 13 MAR 2008
  4. Manuscript Received: 29 AUG 2007

Funded by

  • American Heart Association. Grant Number: 0330118N
  • National Institutes of Health. Grant Numbers: P01 CA093900, RO1 CA100520

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (494K)

References

  • 1
    Karsenty G,Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002; 2: 389–406.
  • 2
    Lacey DL,Timms E,Tan HL,Kelley MJ,Dunstan CR,Burgess T,Elliott R,Colombero A,Elliott G,Scully S,Hsu H,Sullivan J, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–76.
  • 3
    Yasuda H,Shima N,Nakagawa N,Yamaguchi K,Kinosaki M,Mochizuki S,Tomoyasu A,Yano K,Goto M,Murakami A,Tsuda E,Morinaga T, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597–602.
  • 4
    Wada T,Nakashima T,Hiroshi N,Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17–25.
  • 5
    Giles RH,van Es JH,Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1–24.
  • 6
    Logan CY,Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781–810.
  • 7
    He X,Semenov M,Tamai K,Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: arrows point the way. Development 2004; 131: 1663–77.
  • 8
    Moon RT,Kohn AD,De Ferrari GV,Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5: 691–701.
  • 9
    Krishnan V,Bryant HU,Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202–9.
  • 10
    Day TF,Guo X,Garrett-Beal L,Yang Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005; 8: 739–50.
  • 11
    Hill TP,Spater D,Taketo MM,Birchmeier W,Hartmann C. Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005; 8: 727–38.
  • 12
    Holmen SL,Zylstra CR,Mukherjee A,Sigler RE,Faugere MC,Bouxsein ML,Deng L,Clemens TL,Williams BO. Essential role of β-catenin in postnatal bone acquisition. J Biol Chem 2005; 280: 21162–8.
  • 13
    Glass DA2nd,Bialek P,Ahn JD,Starbuck M,Patel MS,Clevers H,Taketo MM,Long F,McMahon AP,Lang RA,Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751–64.
  • 14
    Spencer GJ,Utting JC,Etheridge SL,Arnett TR,Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006; 119: 1283–96.
  • 15
    Jackson A,Vayssière B,Garcia T,Newell W,Baron R,Roman-Roman S,Rawadi G. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 2005; 36: 585–98.
  • 16
    Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–93.
  • 17
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655–64.
  • 18
    Kozlow W,Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10: 169–80.
  • 19
    Tian E,Zhan F,Walker R,Rasmussen E,Ma Y,Barlogie B,Shaughnessy JDJr., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–94.
  • 20
    Hall CL,Bafico A,Dai J,Aaronson SA,Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005; 65: 7554–60.
  • 21
    Gunn WG,Conley A,Deininger L,Olson SD,Prockop DJ,Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24: 986–91.
    Direct Link:
  • 22
    Politou MC,Heath DJ,Rahemtulla A,Szydlo R,Anagnostopoulos A,Dimopoulos MA,Croucher PI,Terpos E. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006; 119: 1728–31.
    Direct Link:
  • 23
    Yaccoby S,Ling W,Zhan F,Walker R,Barlogie B,Shaughnessy JDJr., Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106–11.
  • 24
    Clines GA,Mohammad KS,Bao Y,Stephens OW,Suva LJ,Shaughnessy JD,Jr,Fox JW,Chirgwin JM,Guise TA. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007; 21: 486–98.
  • 25
    Terpos E,Heath DJ,Rahemtulla A,Zervas K,Chantry A,Anagnostopoulos A,Pouli A,Katodritou E,Verrou E,Vervessou EC,Dimopoulos MA,Croucher PI. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688–92.
    Direct Link:
  • 26
    Colla S,Zhan F,Xiong W,Wu X,Xu H,Stephens O,Yaccoby S,Epstein J,Barlogie B,Shaughnessy JDJr., The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 2007; 109: 4470–7.
  • 27
    Schwaninger R,Rentsch CA,Wetterwald A,van der Horst G,van Bezooijen RL,van der Pluijm G,Lowik CW,Ackermann K,Pyerin W,Hamdy FC,Thalmann GN,Cecchini MG. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol 2007; 170: 160–75.
  • 28
    Nusse R,Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31: 99–109.
  • 29
    Peters G,Brookes S,Smith R,Dickson C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell 1983; 33: 369–77.
  • 30
    Nusse R,van Ooyen A,Cox D,Fung YK,Varmus H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984; 307: 131–6.
  • 31
    Dale TC,Weber-Hall SJ,Smith K,Huguet EL,Jayatilake H,Gusterson BA,Shuttleworth G,O'Hare M,Harris AL. Compartment switching of WNT-2 expression in human breast tumors. Cancer Res 1996; 56: 4320–3.
  • 32
    Huguet EL,McMahon JA,McMahon AP,Bicknell R,Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 1994; 54: 2615–21.
  • 33
    Bui TD,Zhang L,Rees MC,Bicknell R,Harris AL. Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br J Cancer 1997; 75: 1131–6.
  • 34
    Ugolini F,Charafe-Jauffret E,Bardou VJ,Geneix J,Adélaïde J,Labat-Moleur F,Penault-Llorca F,Longy M,Jacquemier J,Birnbaum D,Pébusque MJ. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001; 20: 5810–7.
  • 35
    Roh MS,Hong SH,Jeong JS,Kwon HC,Kim MC,Cho SH,Yoon JH,Hwang TH. Gene expression profiling of breast cancers with emphasis of β-catenin regulation. J Korean Med Sci 2004; 19: 275–82.
  • 36
    Lin SY,Xia W,Wang JC,Kwong KY,Spohn B,Wen Y,Pestell RG,Hung MC. β-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000; 97: 4262–6.
  • 37
    Lim SC,Lee MS. Significance of E-cadherin/β-catenin complex and cyclin D1 in breast cancer. Oncol Rep 2002; 9: 915–28.
  • 38
    Chung GG,Zerkowski MP,Ocal IT,Dolled-Filhart M,Kang JY,Psyrri A,Camp RL,Rimm DL. β-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004; 100: 2084–92.
    Direct Link:
  • 39
    Ayyanan A,Civenni G,Ciarloni L,Morel C,Mueller N,Lefort K,Mandinova A,Raffoul W,Fiche M,Dotto GP,Brisken C. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci USA 2006; 103: 3799–804.
  • 40
    Mbalaviele G,Dunstan CR,Sasaki A,Williams PJ,Mundy GR,Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996; 56: 4063–70.
  • 41
    Fujita K,Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG. RANKL and M-CSF. Mol Cancer 2007; 6: 71.
  • 42
    Bafico A,Gazit A,Wu-Morgan SS,Yaniv A,Aaronson SA. Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene 1998; 16: 2819–25.
  • 43
    Bafico A,Liu G,Goldin L,Harris V,Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004; 6: 497–506.
  • 44
    Mi K,Johnson GV. Role of the intracellular domains of LRP5 and LRP6 in activating the Wnt canonical pathway. J Cell Biochem 2005; 95: 328–38.
    Direct Link:
  • 45
    Sasaki A,Boyce BF,Story B,Wright KR,Chapman M,Boyce R,Mundy GR,Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 3551–7.
  • 46
    Yoneda T,Sasaki A,Dunstan C,Williams PJ,Bauss F,De Clerck YA,Mundy GR. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509–17.
  • 47
    Kang Y,Siegel PM,Shu W,Drobnjak M,Kakonen SM,Cordón-Cardo C,Guise TA,Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537–49.
  • 48
    Yoneda T,Williams PJ,Hiraga T,Niewolna M,Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16: 1486–95.
    Direct Link:
  • 49
    Thomas RJ,Guise TA,Yin JJ,Elliott J,Horwood NJ,Martin TJ,Gillespie MT. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451–8.
  • 50
    Silva J,Beckedorf A,Bieberich E. Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells. J Biol Chem 2003; 278: 25376–85.
  • 51
    Bendre MS,Margulies AG,Walser B,Akel NS,Bhattacharrya S,Skinner RA,Swain F,Ramani V,Mohammad KS,Wessner LL,Martinez A,Guise TA, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005; 65: 11001–9.
  • 52
    Fisher JL,Thomas-Mudge RJ,Elliott J,Hards DK,Sims NA,Slavin J,Martin TJ,Gillespie MT. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006; 66: 3620–8.
  • 53
    Niida A,Hiroko T,Kasai M,Furukawa Y,Nakamura Y,Suzuki Y,Sugano S,Akiyama T. DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway. Oncogene 2004; 23: 8520–6.
  • 54
    González-Sancho JM,Aguilera O,García JM,Pendás-Franco N,Peña C,Cal S,García de Herreros A,Bonilla F,Muñoz A. The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/TCF and is downregulated in human colon cancer. Oncogene 2005; 24: 1098–103.
  • 55
    Chamorro MN,Schwartz DR,Vonica A,Brivanlou AH,Cho KR,Varmus HE. FGF-20 and DKK1 are transcriptional targets of β-catenin and FGF-20 is implicated in cancer and development. EMBO J 2005; 24: 73–84.
  • 56
    Yan D,Wiesmann M,Rohan M,Chan V,Jefferson AB,Guo L,Sakamoto D,Caothien RH,Fuller JH,Reinhard C,Garcia PD,Randazzo FM, et al. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA 2001; 98: 14973–8.
  • 57
    Jho EH,Zhang T,Domon C,Joo CK,Freund JN,Costantini F. Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22: 1172–83.
  • 58
    Lustig B,Jerchow B,Sachs M,Weiler S,Pietsch T,Karsten U,van de Wetering M,Clevers H,Schlag PM,Birchmeier W,Behrens J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002; 22: 1184–93.
  • 59
    Leung JY,Kolligs FT,Wu R,Zhai Y,Kuick R,Hanash S,Cho KR,Fearon ER. Activation of AXIN2 expression by β-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 2002; 277: 21657–65.
  • 60
    Liu G,Bafico A,Harris VK,Aaronson SA. A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol Cell Biol 2003; 23: 5825–35.
  • 61
    Forget MA,Turcotte S,Beauseigle D,Godin-Ethier J,Pelletier S,Martin J,Tanguay S,Lapointe R. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007; 96: 646–53.
  • 62
    Yamabuki T,Takano A,Hayama S,Ishikawa N,Kato T,Miyamoto M,Ito T,Ito H,Miyagi Y,Nakayama H,Fujita M,Hosokawa M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007; 67: 2517–25.
  • 63
    Wirths O,Waha A,Weggen S,Schirmacher P,Kühne T,Goodyer CG,Albrecht S,Von Schweinitz D,Pietsch T. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms tumors. Lab Invest 2003; 83: 429–34.
View Full Article (HTML) Get PDF (494K)